JP2011513437A5 - - Google Patents

Download PDF

Info

Publication number
JP2011513437A5
JP2011513437A5 JP2010550000A JP2010550000A JP2011513437A5 JP 2011513437 A5 JP2011513437 A5 JP 2011513437A5 JP 2010550000 A JP2010550000 A JP 2010550000A JP 2010550000 A JP2010550000 A JP 2010550000A JP 2011513437 A5 JP2011513437 A5 JP 2011513437A5
Authority
JP
Japan
Prior art keywords
moiety
cancerous cells
compound
prooxidant
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010550000A
Other languages
English (en)
Japanese (ja)
Other versions
JP5616798B2 (ja
JP2011513437A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2009/000312 external-priority patent/WO2009111846A1/en
Publication of JP2011513437A publication Critical patent/JP2011513437A/ja
Publication of JP2011513437A5 publication Critical patent/JP2011513437A5/ja
Application granted granted Critical
Publication of JP5616798B2 publication Critical patent/JP5616798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010550000A 2008-03-14 2009-03-16 ミトコンドリア由来の抗ガン化合物 Active JP5616798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008901261 2008-03-14
AU2008901261A AU2008901261A0 (en) 2008-03-14 Mitochondrially Delivered Anti-Cancer Compounds
PCT/AU2009/000312 WO2009111846A1 (en) 2008-03-14 2009-03-16 Mitochondrially delivered anti-cancer compounds

Publications (3)

Publication Number Publication Date
JP2011513437A JP2011513437A (ja) 2011-04-28
JP2011513437A5 true JP2011513437A5 (https=) 2013-05-02
JP5616798B2 JP5616798B2 (ja) 2014-10-29

Family

ID=41064682

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010550000A Active JP5616798B2 (ja) 2008-03-14 2009-03-16 ミトコンドリア由来の抗ガン化合物

Country Status (7)

Country Link
US (2) USRE47300E1 (https=)
EP (1) EP2265623B1 (https=)
JP (1) JP5616798B2 (https=)
KR (1) KR101642157B1 (https=)
CA (1) CA2734208C (https=)
NZ (1) NZ602579A (https=)
WO (1) WO2009111846A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103764026B (zh) 2011-04-14 2016-10-19 艾伦斯生物科技有限公司 用于肝细胞癌的诊断、预后、监测和治疗的方法
WO2012174287A1 (en) * 2011-06-15 2012-12-20 The Board Of Regents Of The University Of Texas System Luminescent nanoparticle compositions
HK1200459A1 (en) 2011-09-19 2015-08-07 Gencia Corporation Modified creatine compounds
WO2013181488A2 (en) * 2012-06-01 2013-12-05 The Ohio State University Research Foundation Inhibition of leukemic stem cells by pp2a activating agents
PT2989110T (pt) * 2013-04-24 2018-11-15 Jira­ Neuzil Derivados de tamoxifeno para o tratamento de doenças neoplásicas, especialmente com nível elevado de proteína her2
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
WO2016144637A1 (en) * 2015-03-06 2016-09-15 The Children's Hospital Of Philadelphia Tocopheryloxyacetate ester-based co-drug conjugates
CZ307146B6 (cs) * 2015-03-31 2018-02-07 Kkcg Se Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva
US20180318324A1 (en) 2015-11-04 2018-11-08 Prescient Pharma Llc Anti-aging compositions and methods for using same
KR102361131B1 (ko) * 2020-02-25 2022-02-10 경희대학교 산학협력단 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물
TW202233246A (zh) * 2020-10-22 2022-09-01 南韓商白雁生物技術公司 含有抗癌劑之粒線體及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) * 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
KR100847678B1 (ko) 2000-02-11 2008-07-23 리서치 디벨럽먼트 파운데이션 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도
AUPQ605800A0 (en) * 2000-03-06 2000-03-30 Silverbrook Research Pty Ltd Printehead assembly
WO2002093063A1 (en) * 2001-05-17 2002-11-21 Imperial College Innovations Limited Production and processing plant with a rigid pipe portion curving in three dimensions
BRPI0413742B8 (pt) 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
CN1925853B (zh) * 2004-07-28 2011-01-26 陈献 琥珀酸α-生育酚酯及其类似物和盐的稳定注射组合物
KR100556527B1 (ko) * 2004-11-04 2006-03-06 삼성전자주식회사 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법
WO2006094203A1 (en) 2005-03-02 2006-09-08 Northeastern University Mitochondriotropic phospholipid vesicles
RU2318500C2 (ru) 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
NZ575920A (en) 2006-09-15 2012-08-31 Stephen John Ralph Pro-oxidant anti-cancer compounds
JP4930026B2 (ja) * 2006-12-13 2012-05-09 富士ゼロックス株式会社 積層体、無端状ベルト、定着装置及び画像形成装置
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung

Similar Documents

Publication Publication Date Title
JP2011513437A5 (https=)
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
JP2016517434A5 (https=)
JP2010525050A5 (https=)
JP2020514412A5 (https=)
WO2009111846A4 (en) Mitochondrially delivered anti-cancer compounds
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
NZ595767A (en) Composition for the treatment of prostate cancer
WO2019130215A1 (en) Cannabis compositions for the treatment of inflammatory skin disorders
WO2014180239A1 (zh) 一种治疗重症高原病的药物组合物
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
NO20080244L (no) Doseringsstyring for prasugrel
JP2016505050A5 (https=)
CN104337916A (zh) 一种手脚冰凉及脚气的中药药剂
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
ES2950096T3 (es) Método para aliviar los síntomas del síndrome premenstrual
CN101933963A (zh) 一种治疗头痛的鼻用原位凝胶剂
CN101439160A (zh) 玉米提取物防治肿瘤的用途
CN105535003A (zh) 金盏花苷e在制备治疗抗肿瘤药物中的用途
TWI469784B (zh) 可治療癌症之藥學組合物
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
CN102631421A (zh) 一种治疗老年痴呆病的中药
CN105497003B (zh) 淫羊藿苷元在制备预防或治疗肺纤维化药物中的应用
CN101856359A (zh) 一种抗急性髓系白血病的药物组合物
CN103371987B (zh) 漆酚化合物在制备抑制肾脏组织纤维化的药物中的用途